LTBP4 and hereditary cancer: To further explore a potential role of LTBP4 inactivation in CRC predisposition, we assessed the presence of rare germline LTBP4 damaging or predicted damaging variants in two cohorts: i) 36 Dutch and 14 Spanish familial and/or early-onset MMR-proficient nonpolyposis CRC patients without  germline pathogenic variants in known hereditary cancer genes; and ii) 632 Dutch patients with metastatic CRC.